Long-term clinical experience with vedolizumab for the treatment of inflammatory bowel disease
A. Parikh(Takeda (United States)), Brian G. Feagan(Western University), Irving H. Fox(Takeda (United States)), Michael Patella(Millennium Engineering and Integration (United States)), Jing Xu(Soochow University), Timothy Leach(Takeda (United States))
Cited by 5
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k